32 Article(s)Download |
||||||
PMID | Title | Pub. Year | #Total Relationships |
|||
1 | 31595792 | Adipokine gene expression in adipocytes isolated from different fat depots of coronary artery disease patients. | 2022 Feb | 1 | ||
2 | 33342939 | Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy. | 2022 Jan 1 | 1 | ||
3 | 33538983 | Decrease of dipeptidyl peptidase 4 activity is associated with weight loss after bariatric surgery. | 2021 Jun | 2 | ||
4 | 33737166 | Expectations for synergistically favorable effects of the combination therapy with DPP-4 inhibitor and SGLT2 inhibitor on cholesterol synthesis and absorption. | 2021 Jun 15 | 1 | ||
5 | 34333803 | Efficacy and safety profile of sitagliptin, vildagliptin, and metformin in newly diagnosed type 2 diabetic subjects. | 2021 Dec | 1 | ||
6 | 34926239 | DPP4 Regulates DHCR24-Mediated Cholesterol Biosynthesis to Promote Methotrexate Resistance in Gestational Trophoblastic Neoplastic Cells. | 2021 | 5 | ||
7 | 31990936 | Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial. | 2020 | 2 | ||
8 | 32422444 | Serum Dipeptidyl peptidase-4 level is related to adiposity in type 1 diabetic adolescents. | 2020 Jul - Aug | 1 | ||
9 | 30302966 | Soluble Dipeptidyl Peptidase-4 Levels Are Associated with Decreased Renal Function in Patients with Type 2 Diabetes Mellitus. | 2019 Feb | 1 | ||
10 | 30674032 | Pharmacology of dipeptidyl peptidase-4 inhibitors and its use in the management of metabolic syndrome: a comprehensive review on drug repositioning. | 2019 Jun | 1 | ||
11 | 30738832 | Oxidized LDL upregulates macrophage DPP4 expression via TLR4/TRIF/CD36 pathways. | 2019 Mar | 1 | ||
12 | 31733647 | Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial. | 2019 Nov 16 | 1 | ||
13 | 28403877 | A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes. | 2017 Apr 13 | 2 | ||
14 | 31089516 | Association between Serum Dipeptidyl Peptidase-4 Concentration and Obesity-related Factors in Health Screen Examinees. | 2017 Sep | 1 | ||
15 | 26752504 | Determinants of Glycemic Response to Add-On Therapy with a Dipeptidyl Peptidase-4 Inhibitor: A Retrospective Cohort Study Using a United Kingdom Primary Care Database. | 2016 Feb | 1 | ||
16 | 27006706 | Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus. | 2016 | 1 | ||
17 | 27693949 | Persons with latent autoimmune diabetes in adults express higher dipeptidyl peptidase-4 activity compared to persons with type 2 and type 1 diabetes. | 2016 Nov | 1 | ||
18 | 25294850 | Increased plasma dipeptidyl peptidase 4 activities predict new-onset microalbuminuria in association with its proinflammatory effects in Chinese without diabetes: a four-year prospective study. | 2015 Mar | 1 | ||
19 | 26048437 | Comparisons of the efficacy of glucose control, lipid profile, and β-cell function between DPP-4 inhibitors and AGI treatment in type 2 diabetes patients: a meta-analysis. | 2015 Dec | 2 | ||
20 | 26259132 | Plasma DPP4 Activities Are Associated With Osteoporosis in Postmenopausal Women With Normal Glucose Tolerance. | 2015 Oct | 2 | ||
21 | 26474470 | Serum Levels of Soluble CD26/Dipeptidyl Peptidase-IV in Type 2 Diabetes Mellitus and Its Association with Metabolic Syndrome and Therapy with Antidiabetic Agents in Malaysian Subjects. | 2015 | 2 | ||
22 | 26603933 | Glucagon-like peptide 1 (GLP-1)-based therapy upregulates LXR-ABCA1/ABCG1 cascade in adipocytes. | 2015 Dec 25 | 1 | ||
23 | 25110536 | Effect of sitagliptin on lipid profile in patients with type 2 diabetes mellitus. | 2014 Oct | 1 | ||
24 | 23379505 | Comparison of the dipeptidyl peptidase-4 gene methylation levels between severely obese subjects with and without the metabolic syndrome. | 2013 Feb 4 | 1 | ||
25 | 23994650 | The serum level of soluble CD26/dipeptidyl peptidase 4 increases in response to acute hyperglycemia after an oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes. | 2013 Nov | 1 | ||
26 | 24362783 | [Effects of anti-diabetic therapy on overweight/obesity and dyslipidemia: traditional hypoglycemic agents (metformin, sulfonylureas, thiazolidinediones) versus glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors]. | 2013 Dec | 2 | ||
27 | 22179204 | Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism. | 2012 Mar | 1 | ||
28 | 22215383 | DPP-4 inhibitors and lipids: systematic review and meta-analysis. | 2012 Jan | 7 | ||
29 | 22398368 | 5-Aza-2'-deoxycytidine induced growth inhibition of leukemia cells through modulating endogenous cholesterol biosynthesis. | 2012 Jul | 2 | ||
30 | 22785237 | Plasma dipeptidyl peptidase 4 activity correlates with body mass index and the plasma adiponectin concentration in healthy young people. | 2012 | 1 | ||
31 | 22923161 | Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials. | 2012 Sep | 1 | ||
32 | 11773049 | Intestinal dipeptidyl peptidase IV is efficiently sorted to the apical membrane through the concerted action of N- and O-glycans as well as association with lipid microdomains. | 2002 Mar 22 | 3 |